Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.98 |
| ▸ | PGR | P06401 | 3/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.98 |
| ▸ | AR | P10275 | 2/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | APEX1 | P27695 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | IKBKB | O14920 | 1/20 | 0.98 |
| ▸ | CHUK | O15111 | 1/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.98 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.98 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.98 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexamethasone SCHEMBL364920 | 1.00 | HIF1A (0.98) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL4847833 | 0.99 | HIF1A (0.96) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL4847837 | 0.99 | HIF1A (0.96) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL3392690 | 0.99 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21790369 | 0.99 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL23022353 | 0.99 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL21261932 | 0.99 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL20816248 | 0.99 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL11911310 | 0.99 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL12738245 | 0.99 | HIF1A (1.00) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117858663-A | Films with biodegradable polymers | 豪夫迈·罗氏有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-3757136-B1 | CHONDROITIN SULFATE DERIVATIVE AND AGENT FOR TREATING BLADDER DISEASES | SEIKAGAKU KOGYO CO LTD (JP) | 2023-07-19 | — | — | EP | disclosed |
| US-20230116809-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | ASCENDIS PHARMA OPHTHALMOLOGY DIVISION A/S (DK) | 2023-04-13 | — | — | US | disclosed |
| CN-112912128-B | Implant needle and kit | 豪夫迈·罗氏有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-113616656-B | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders | 无限药品股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-114040720-A | Insertion needle for inserting a subcutaneous insertable element into body tissue | 豪夫迈·罗氏有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-112912128-A | Implant needle and kit | 豪夫迈·罗氏有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-110545850-A | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB | 2019-12-06 | — | — | CN | disclosed |
| EP-2532738-B1 | METHOD FOR CULTURE OF CORNEAL ENDOTHELIAL CELLS, PROCESS FOR PRODUCTION OF CORNEAL ENDOTHELIAL CELL SHEET FOR TRANSPLANTATION PURPOSES, AND CULTURE KIT FOR CORNEAL ENDOTHELIAL CELLS | CORNEA REGENERATION INST CO LTD (JP) | 2016-12-21 | — | — | EP | disclosed |
| US-20160257931-A1 | METHOD FOR CULTURE OF CORNEAL ENDOTHELIAL CELLS, PROCESS FOR PRODUCTION OF CORNEAL ENDOTHELIAL CELL SHEET FOR TRANSPLANTATION PURPOSES, AND CULTURE KIT FOR CORNEAL ENDOTHELIAL CELLS | CORNEA REGENERATION INSTITUTE CO., LTD. (JP) | 2016-09-08 | — | — | US | disclosed |
| US-9376661-B2 | Method for culture of corneal endothelial cells, process for production of corneal endothelial cell sheet for transplantation purposes, and culture kit for corneal endothelial cells | CORNEA REGENERATION INSTITUTE CO., LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| US-20130023050-A1 | METHOD FOR CULTURE OF CORNEAL ENDOTHELIAL CELLS, PROCESS FOR PRODUCTION OF CORNEAL ENDOTHELIAL CELL SHEET FOR TRANSPLANTATION PURPOSES, AND CULTURE KIT FOR CORNEAL ENDOTHELIAL CELLS | FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION (JP) | 2013-01-24 | — | — | US | disclosed |
| EP-2532738-A1 | METHOD FOR CULTURE OF CORNEAL ENDOTHELIAL CELLS, PROCESS FOR PRODUCTION OF CORNEAL ENDOTHELIAL CELL SHEET FOR TRANSPLANTATION PURPOSES, AND CULTURE KIT FOR CORNEAL ENDOTHELIAL CELLS | Foundation for Biomedical Research and Innovation (JP) | 2012-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116809-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | NR3C1 1285/4885HIF1A 336/4885CYP3A4 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.